Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Paradoxical Reaction to Rituximab in Patients With Pemphigus: A Report of 10 Cases Publisher Pubmed



Nili A1 ; Tavakolpour S1 ; Mahmoudi H1 ; Noormohammadpour P1 ; Balighi K1 ; Daneshpazhooh M1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran

Source: Immunopharmacology and Immunotoxicology Published:2020


Abstract

[No abstract available]
Related Docs
View other Related Docs
1. Rituximab in Practice: Clinical Evaluation of Patients With Pemphigus After Rituximab Administration, Dermatologic Therapy (2021)
2. Single-Nucleotide Polymorphisms Associated With Pemphigus Vulgaris: Potent Markers for Better Treatment and Personalized Medicine, International Journal of Immunogenetics (2020)
3. Efficacy and Safety of Biosimilar Rituximab in Patients With Pemphigus Vulgaris: A Prospective Observational Study, Journal of Dermatological Treatment (2021)
4. A Systematic Review on Efficacy, Safety, and Treatment-Durability of Low-Dose Rituximab for the Treatment of Pemphigus: Special Focus on Covid-19 Pandemic Concerns, Immunopharmacology and Immunotoxicology (2021)
5. Covid-19: The Experience From Iran, Clinics in Dermatology (2021)
6. Intralesional Injection of Biosimilar Rituximab in Recalcitrant Mucocutaneous Lesions of Patients With Pemphigus Vulgaris: A Pilot Study, Dermatologic Therapy (2020)
7. Comparison of Topical Nanocolloidal Silver Formulation Use With Eosin 2% Solution in Management of Hard-To-Heal Ulcers in Patients With Pemphigus Vulgaris, Journal of Wound Care (2020)
8. Applicability of Glucocorticoid Toxicity Index in Pemphigus: Comparison Between Two Groups of Rituximab-Treated and Rituximab-Naive Patients, Dermatologic Therapy (2022)
Experts (# of related papers)
View all Related Experts
Maryam Daneshpajooh (27)
Hamid Reza Mahmoodi (24)
Other Related Docs
9. Elevated Serum Level of B-Cell Activating Factor (Baff) After Rituximab Therapy in Pemphigus Vulgaris Patients Suggests a Possible Therapeutic Efficacy of B-Cell Depletion Therapies Combined With Anti-Baff Agents, International Journal of Dermatology (2023)
10. Comparing Early and Late Treatments With Rituximab in Pemphigus Vulgaris: Which One Is Better?, Archives of Dermatological Research (2019)
11. Short-Term Clinical and Serological Follow-Up With Conventional and Conformational Anti-Desmoglein Antibodies in Treatment-Naive and Previously Treated Patients With Pemphigus Vulgaris After Receiving Rituximab, International Journal of Women's Dermatology (2019)
12. Pathogenic and Protective Roles of Cytokines in Pemphigus: A Systematic Review, Cytokine (2020)
13. Unexpected Worsening of Pemphigus Vulgaris After Rituximab: A Report of Three Cases, International Immunopharmacology (2019)
14. Sixteen-Year History of Rituximab Therapy for 1085 Pemphigus Vulgaris Patients: A Systematic Review, International Immunopharmacology (2018)
15. Tofacitinib As the Potent Treatment for Refractory Pemphigus: A Possible Alternative Treatment for Pemphigus, Dermatologic Therapy (2018)
16. Burden of Pemphigus Vulgaris With a Particular Focus on Women: A Review, International Journal of Women's Dermatology (2022)
17. Iranian Guideline for Rituximab Therapy in Pemphigus Patients, Dermatologic Therapy (2019)
18. Pemphigus Disease and Area Index: Unmet Needs in the Real-World Management of Pemphigus, Oral Diseases (2023)
19. Prevalence of Fungal Infections in Pemphigus Patients: A Systematic Review and Meta-Analysis, Mycoses (2024)
20. Updated S2k Guidelines on the Management of Pemphigus Vulgaris and Foliaceus Initiated by the European Academy of Dermatology and Venereology (Eadv), Journal of the European Academy of Dermatology and Venereology (2020)
21. Pregnancy Outcomes in Women With Pemphigus Exposed to Rituximab Before or During Pregnancy, International Journal of Women's Dermatology (2022)
22. Investigating Expression Pattern of Eight Immune-Related Genes in Pemphigus Patients Compared With the Healthy Controls and After Rituximab Therapy: Potential Roles of Ctla4 and Fcgr3a Genes Expression in Outcomes of Rituximab Therapy, Dermatologic Therapy (2020)
23. Rituximab Monotherapy in Mild Pemphigus, Journal of Dermatological Treatment (2022)
24. The Efficacy of Rituximab in Patients With Mucous Membrane Pemphigoid, Journal of Dermatological Treatment (2022)
25. Anti-Desmoglein-1 Levels As Predictor of Prednisolone Tapering in Pemphigus Vulgaris Patients Treated With Rituximab, Dermatologic Therapy (2018)
26. Rituximab in Childhood and Juvenile Autoimmune Bullous Diseases As First-Line and Second-Line Treatment: A Case Series of 13 Patients, Journal of Dermatological Treatment (2020)
27. Comparing the Short-Term Therapeutic Effects and Safety Profiles of Rituximab Therapy in Pemphigus Vulgaris Patients Either Early Treated or Later Than Six Months, Journal of Dermatological Treatment (2019)
28. Drug-Induced Pemphigus: A Systematic Review of 170 Patients, International Immunopharmacology (2021)
29. Retrospective Study of Gingival Involvement in Pemphigus: A Difficult to Treat Phenomenon, Dermatologic Therapy (2022)